{"nct_id":"NCT01140347","title":"A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib","status":"COMPLETED","status_verified_date":"2015-11","start_date":"2010-10","start_date_type":null,"primary_completion_date":"2014-03","primary_completion_date_type":"ACTUAL","completion_date":"2015-03","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["LLY"]}